News Industry Updates Medical Research
Biopharma company hopes to treat rare skin diseases with CBN

A Vancouver-based pharmaceutical company is researching a rare cannabinoid for its therapeutic benefits.

InMed Pharmaceuticals Inc. has launched a new website outlining its clinical development of cannabinol, or CBN, which the company believes has greater advantages over cannabiodiol (CBD) and tetrahydrocannabinol (THC) in treating “diseases with high unmet medical need.”

“We’re very glad to be the first company globally to bring forth a specific rare cannabinoid called cannabinol, or CBN, into human clinical trials, looking at its use as a therapeutic product,” said CEO Eric A. Adams in an interview with Edison Research. “It’s a product that we’ve had under research and development for the last three, four years. We’ve been making great progress with it and we’ve now entered the stage of healthy human clinical trials in the Netherlands with this cannabinol-based skin cream.”

The company website explains that this rare cannabinoid, which can be found in trace amounts in the cannabis plant, could have potential for treating a number of dermal diseases and even a potential treatment for glaucoma, which is an eye disease.

INM-755 is InMed’s dermatological product candidate for treating symptoms related to a rare genetic skin disease called Epidermolysis bullosa or EB. This genetic condition results in easy blistering and extensive wounds caused by minor trauma to the skin. InMed’s CBN-based topical cream promises to relieve pain and inflammation, as well as enhance skin integrity of its users. This product is currently undergoing Phase 1 clinical trials.

InMed is also developing INM-088 as a potential treatment for ocular disease. Currently under clinical testing and advanced formulation development, this topical product candidate is said to decrease intraocular pressure and provide neuroprotection for those suffering from glaucoma.